Federal Circuit Upholds Broad FDA Safe Harbor Interpretation in Edwards Lifesciences Case Against Meril Life Sciences
In a significant development for patent law, the Federal Circuit on Wednesday declined to reconsider its previous decision affirming the dismissal of Edwards Lifesciences’ infringement suit against Meril Life Sciences. The core of Edwards Lifesciences’ argument centered on urging the court to narrow its interpretation of a U.S. Food and Drug Administration (FDA) safe harbor…